1245157-85-0

Basic information

• Product Name: 2-(4-(6-((5-((2-chloro-6-Methylphenyl)carbaMoyl)thiazol-2-yl)aMino)-2-MethylpyriMidin-4-yl)piperazin-1-yl)ethyl acetate
• Synonyms: 2-(4-(6-((5-((2-chloro-6-Methylphenyl)carbaMoyl)thiazol-2-yl)aMino)-2-MethylpyriMidin-4-yl)piperazin-1-yl)ethyl acetate;2-(4-(6-((5-((2-Chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)-amino)-2-methylpyrimidin-4-yl)pi
• CAS NO: 1245157-85-0
• Molecular Formula: C₂₄H₂₈ClN₇O₃S
• Molecular Weight: 530.04222
• Mol File: 1245157-85-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.375±0.06 g/cm3(Predicted)
• PKA: 10.94±0.70(Predicted)
• CAS DataBase Reference: 2-(4-(6-((5-((2-chloro-6-Methylphenyl)carbaMoyl)thiazol-2-yl)aMino)-2-MethylpyriMidin-4-yl)piperazin-1-yl)ethyl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-(6-((5-((2-chloro-6-Methylphenyl)carbaMoyl)thiazol-2-yl)aMino)-2-MethylpyriMidin-4-yl)piperazin-1-yl)ethyl acetate(1245157-85-0)
• EPA Substance Registry System: 2-(4-(6-((5-((2-chloro-6-Methylphenyl)carbaMoyl)thiazol-2-yl)aMino)-2-MethylpyriMidin-4-yl)piperazin-1-yl)ethyl acetate(1245157-85-0)

Safety Data

• Hazardous Substances Data: 1245157-85-0(Hazardous Substances Data)

Usage

General Description

The chemical "2-(4-(6-((5-((2-chloro-6-Methylphenyl)carbaMoyl)thiazol-2-yl)aMino)-2-MethylpyriMidin-4-yl)piperazin-1-yl)ethyl acetate" is an organic compound that contains a piperazine and pyrimidine core structure. It also contains a thiazole ring and a carbamide moiety. The presence of an acetate group in the molecule indicates that it is likely a derivative of acetic acid. This complex chemical structure suggests that it may have potential pharmacological or biological activities, and further study and research are necessary to fully understand its properties and potential applications.

Upstream product

• 1749-68-4 4-amino-6-chloro-2-methylpyrimidine 
• 64-19-7 acetic acid 
• 302962-49-8 dasatanib 
• 1161763-15-0 4-amino-6-bromo-2-methylpyrimidine 
• 1245157-47-4 ethyl 2-(6-bromo-2-methylpyrimidin-4-ylamino)thiazole-5-formate 
• 1245157-80-5 2-[[6-[4-(2-acetoxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxylic acid 
• 1245157-42-9 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-formic acid 
• 1245157-41-8 isopropyl 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-formate 
• 1245157-39-4 ethyl (6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-formate 
• 1245157-35-0 methyl 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-formate 
• 1245157-49-6 isopropyl 2-(6-bromo-2-methylpyrimidin-4-ylamino)thiazole-5-formate 
• 1245157-45-2 methyl 2-(6-bromo-2-methylpyrimidin-4-ylamino)thiazole-5-formate 
• 127116-19-2 2-(4-(6-chloro-2-methylpyrimidin-4-yl)piperazin-1-yl)ethanol 
• 1245158-44-4 2-(6-(4-(2-acetoxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-formyl chloride 

Downstream Products

• 302962-49-8 dasatanib 

Relevant articles and documents

Design, Synthesis, and Evaluation of Dasatinib–Amino Acid and Dasatinib–Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors

Derivatives of the tyrosine kinase inhibitor dasatinib were synthesized by esterification with 25 carboxylic acids, including amino acids and fatty acids, thereby extending the drug to interact with more diverse sites and to improve specificity. The dasatinib–l-arginine derivative (Das-R, 7) was found to be the most potent of the inhibitors tested, with IC50values of 4.4, 10) with an IC50value of 3.2 μm for Csk compared with 35 nm for Src. Furthermore, many compounds displayed increased selectivity toward Src over Abl. Compounds 15 (Das–glutamic acid) and 13 (Das–cysteine) demonstrated the largest gains (10.2 and 10.3 Abl/Src IC50ratios). Das-R (IC50=2.06 μm) was significantly more potent than the parent dasatinib (IC50=26.3 μm) against Panc-1 cells, whereas both compounds showed IC5051.2 pm against BV-173 and K562 cells. Molecular modeling and binding free energy simulations revealed good agreements with the experimental results and rationalized the differences in selectivity among the studied compounds. Integration of experimental and computational approaches in the design and biochemical screening of dasatinib derivatives facilitated rational engineering and diversification of the dasatinib scaffold, providing useful insight into mechanisms of kinase selectivity.

SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF

Synthesis process of dasatinib is disclosed, which includes the step of reacting the compound of formula I with that of formula II to obtain the compound of formula III. Also disclosed is the compound of formula III which is used as an intermediate for synthesizing dasatinib. The substituents of R1, R2, R3 or R4 in formulae I, II or III are defined as in the description.